The ROI of AI Voice Agents for Rheumatology Billing

Rheumatology bills for some of the most expensive drugs a small practice ever touches. A single biologic infusion claim can run into the thousands, and the buy-and-bill model means the practice often pays for the drug before the payer pays the practice. When a high-dollar claim gets denied and nobody works it before the appeal window closes, the group is out real cash, not just projected revenue.

The story in most rheumatology offices is not that the billing team is weak. It is that the team is buried under prior auth, infusion scheduling, and claims work at the same time. Whatever is on fire that day gets handled, and the structured denial follow-up on drug claims quietly slides.

Why rheumatology denials outrun the billing team

The revenue cycle is a stack of deadlines, and biologics stack them high. Prior authorization on the drug. Step therapy paperwork. Timely-filing windows that vary by payer. Appeal clocks that start the day a denial posts. Miss any one and a claim worth thousands is gone, no matter how medically appropriate the therapy was.

Denials are not rare, and most never get appealed. An analysis of in-network claims in ACA marketplace plans found insurers denied a meaningful share of submissions, and only a small fraction of those denials were ever challenged (KFF). For a rheumatology practice that fronts drug costs, an un-worked denial is money already spent and not recovered.

The follow-up is structured and repetitive, which is why it gets deprioritized. Checking claim status on a payer portal, capturing a denial reason, requesting a corrected remittance, calling a patient about an infusion balance. None of it needs a certified coder. All of it needs someone with a phone and time on the clock.

What an AI voice agent actually does in the revenue cycle

Pretty Good AI builds voice agents that handle the administrative calls in your billing workflow, integrated with athenahealth. The agent is a front-office layer. It does not decide what care a patient needs, and it does not make coding calls that require a certified coder. It works the phone-and-portal grind that keeps money moving.

On the payer side, the agent places outbound status calls on pended and denied claims, captures the denial reason and any reference number, and writes it back into athenaOne so a biller can act. On the patient side, it calls on aged infusion balances, explains what a statement covers, and routes anyone who wants a payment plan or has a question to the right staff member. Before a scheduled infusion, it confirms eligibility and benefits so the practice is not finding a coverage gap after the drug is already ordered.

The goal is not to remove people from revenue cycle work. Denial management and appeals are where experienced billers earn their keep (AAPC). The goal is to stop spending that expensive judgment on hold music.

The revenue math when you front the drug cost

Revenue cycle leaders track the cost to collect and the share of net revenue lost to preventable write-offs, and both improve when follow-up happens on time instead of eventually. In rheumatology the buy-and-bill model raises the stakes because the practice has already paid for the medication. Recovering even one or two denied drug claims a month can pay for the automation several times over.

Run the numbers for your own group. Take your average denied drug-claim value, multiply by the claims that currently age past their appeal window, and you have the annual figure sitting on the table. For a practice carrying biologic inventory, that number is often the difference between a healthy quarter and a tight one.

Keeping it administrative and keeping it clean

Everything the agent does is logistics: status calls, balance calls, benefit confirmation, and routing. When a call surfaces anything that needs a clinician or a certified coder, the agent hands it off with the context already captured. That keeps the practice on the right side of the line. The AI moves information and money, and people make the decisions that require training and licensure.

Key Takeaways

• Biologic and infusion claims carry high dollar values, and the buy-and-bill model means an un-worked denial is cash already spent.
• Follow-up slides because it is repetitive, not because the billing team lacks skill.
• An AI voice agent places payer status calls, works infusion balances, and confirms benefits before scheduled infusions, writing everything back to athenaOne.
• Keep billers and certified coders on appeals and coding judgment, and put the phone-and-portal grind on automation.
• Calculate your exposure: average denied drug-claim value times denials aging past appeal deadlines equals annual revenue at risk.

Rheumatology billing does not fail because your team is not good enough. It fails because there are more deadlines than there are hours, and the claims at risk are the ones you already paid for. Give the repetitive follow-up to a voice agent and let your billers spend their day on the appeals and coding work that actually needs them.

Sources

• https://www.kff.org/private-insurance/issue-brief/claims-denials-and-appeals-in-aca-marketplace-plans/
• https://www.aapc.com/resources/what-is-medical-billing